GSK discontinues genital herpes vaccine after Phase III failure

The most advanced vaccine in development to protect against genital herpes disease in woman, GlaxoSmithKline's Simplirix, has unexpectedly failed in a large Phase III trial, leading the company to discontinue its development.

The most advanced vaccine in development to protect against genital herpes disease in woman, GlaxoSmithKline's Simplirix, has unexpectedly failed in a large Phase III trial, leading the company to discontinue its development.

The Herpevac Trial for Women was conducted collaboratively with the US National Institute of Allergy and Infectious Diseases (NIAID), part...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category